IDT Biologika, a German CDMO (contract development and manufacturing organization) and a wholly owned subsidiary of SK bioscience, is accelerating its global business expansion through a series of appearances at major international biotechnology and pharmaceutical events.

Most recently, the company participated in BioProcess International Europe (BPI Europe), held from May 12 to 15 in Hamburg, Germany. BPI Europe is a key global conference covering end-to-end biopharmaceutical development and manufacturing. During the four-day event, IDT highlighted its integrated service capabilities in virus vaccines, gene and immunotherapies, and sterile injectables. The company also presented multiple case studies of successful partnerships.

Federico Pollano, Chief Commercial Officer, and Dr. Nanette Schlatermund, Senior Expert Business Development, attended the event in person to engage with potential partners and discuss opportunities in next-generation biologics manufacturing.

This follows IDT’s participation in other high-profile industry gatherings, including DCAT Week 2025 in New York in March and the World Vaccine Congress in Washington, D.C. in April.

During DCAT Week, IDT hosted strategic meetings with biopharma leaders, while at the vaccine congress, the company showcased its scale-up expertise using the iCELLis 500 bioreactor platform for both vaccine and cell and gene therapy production.

IDT is also scheduled to attend the BIO International Convention in Boston this June, further continuing its global outreach efforts.

Acquired by SK bioscience in October 2024, IDT has more than a century of operational history and a client base that spans multinational pharmaceutical firms and government agencies across North America, Europe, and Asia.

In the fourth quarter of 2024, SK bioscience posted revenue of 156.8 billion won, marking a 73 percent increase from the same period a year earlier. IDT Biologika is targeting annual sales of over 410 billion won this year.

“IDT’s selection as a 2025 CDMO Leadership Award winner in the biologics category underscores our technical expertise, customer satisfaction, and global credibility,” IDT Biologika Co-CEO Sally Choe said. “We will continue to build on our differentiated customer-centric services and global partnerships to drive growth in the CDMO sector.”